However, comprehensive analysis by both phosphoproteomics and transcriptomics in ABC-DLBCL cell lines to elucidate the anti-tumor mechanism of BTK inhibitors has not been reported previously. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.